about
Non-invasive vulnerable plaque imaging: how do we know that treatment works?Bone health in children with long-term idiopathic subclinical hypothyroidism.Comparison of the prognostic value of SPECT after nitrate administration and metabolic imaging by PET in patients with ischaemic left ventricular dysfunction.Functional characterization of brain tumors: an overview of the potential clinical value.Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.Combination of docetaxel and cetuximab for penile cancer: a case report and literature review.Comparison of left ventricular shape by gated SPECT imaging in diabetic and nondiabetic patients with normal myocardial perfusion: A propensity score analysis.The role of scintigraphic defecography in the assessment of bowel function after restorative proctocolectomy for ulcerative colitis.Extra-osseous 99mTc methylene diphosphonate uptake detected enlargement of the knee joint in patient with polyarthritis.Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents.Prognostic value of atherosclerotic burden and coronary vascular function in patients with suspected coronary artery disease.Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.Excellent prognosis and prevalence of HCV infection of primary hepatic and splenic non-Hodgkin’s lymphomaIn vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patientsTc-99m MIBI scintigraphy in patients with lung cancer. Comparison with CT and fluorine-18 FDG PET imagingNoninvasive quantification of coronary endothelial function by SPECT imaging in children with a history of Kawasaki diseaseThe treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center
P50
Q27020959-89572861-72DB-467A-8543-B471797AB107Q36356406-91581B39-65CE-4A2A-921F-BB30FF1DE942Q36688639-842A3AE6-3C97-4AF2-B048-79B855A947D8Q36835088-E198D105-0C63-46D3-B961-B34E87869318Q37324886-84C40F80-8B95-46A2-976E-7ABE5D897F93Q38000450-A8D03B49-C99F-453A-948C-42CAC3D76396Q38624586-B13F41DB-3BBE-4F41-8C71-70B187F235BAQ43333223-0E48A63D-0C3D-4459-ADF8-12CB9320E7C2Q45918255-9BAE5A6F-7AF1-445C-B686-C285AE286BF2Q45948615-B5CB39FD-CA85-4D85-A03B-01CF1C74F413Q48227877-0508EB83-DB19-4821-9454-2777B32B0221Q50092725-6DE2348D-96D2-4919-85C5-629CB8ACC1AEQ61929002-C5611F79-601A-4EBB-8500-671D98CED29EQ73041298-B358BBAF-D7B8-432F-BEC4-0A73033D6C42Q73214883-9E2BE1A7-4892-4CEC-BC7D-DB6D55F1AA77Q84640580-219C04C7-7D99-4549-BB86-865F4029302EQ86874227-BFD9F7AB-0F3D-41C8-B17B-2763FE6BD95E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ciro Gabriele Mainolfi
@ast
Ciro Gabriele Mainolfi
@en
Ciro Gabriele Mainolfi
@es
Ciro Gabriele Mainolfi
@nl
type
label
Ciro Gabriele Mainolfi
@ast
Ciro Gabriele Mainolfi
@en
Ciro Gabriele Mainolfi
@es
Ciro Gabriele Mainolfi
@nl
prefLabel
Ciro Gabriele Mainolfi
@ast
Ciro Gabriele Mainolfi
@en
Ciro Gabriele Mainolfi
@es
Ciro Gabriele Mainolfi
@nl
P106
P1153
6602866112
P21
P31
P496
0000-0002-1727-1953